Sanofi has settled a long-running dispute with shareholders in the biotech Genzyme, who claimed the big pharma deliberately held back development of a multiple sclerosis drug to avoid payments ...

The company remains convinced of the product's merits and—bolstered by the backing of a $1.38 billion deal from Genzyme a year ago—continues to pursue cardiac and other autoimmune indications.

Sanofi won approval for the use of a drug combination with its Sarclisa infusion to treat certain types of newly diagnosed ...

One of biotech's biggest collaboration deals on record surfaced on 7 January when Genzyme told analysts and investors that it had signed a potential $1.9 billion agreement with Isis ...

Rachel Sha has had a colorful career not without its challenges, but she urges women in the science industry to have ...

© 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and ...

Chesbrough, Henry W., and Clarissa Ceruti. "Genzyme: Engineering the Market for Orphan Drugs." Harvard Business School Case 602-147, March 2002. (Revised May 2002.) ...

As we have mentioned in our article, “10 Best Penny Stocks to Buy Under $1," the size of the global biotechnology industry ...

Sanofi said on Monday the U.S. Food and Drug Administration has approved a manufacturing line for its and partner AstraZeneca ...

Women were less likely than men to be treated for relapsing multiple sclerosis (MS), French registry data showed. Women had a ...

We recently compiled a list of the 12 Best Biotech Stocks To Invest In According To Hedge Funds. In this article, we are ...

MS experts are recommending updates to the 2017 McDonald diagnostic criteria that aim to make diagnosis easier, faster and more accurate.